Volume 32, Issue 3 (June 2021)                   Studies in Medical Sciences 2021, 32(3): 175-186 | Back to browse issues page

XML Persian Abstract Print


Assistant Professor, Department of Animal Sciences, College of Agriculture and Natural Resources, Razi University, Kermanshah, Iran (Corresponding Author) , leilasoltani7@yahoo.com
Abstract:   (3308 Views)
Background & Aims: One of the leading causes of death in the world is cancer. In order to find cures with fewer side effects and on the other hand drug resistance problems that exist in relation to the treatment of cancer patients, attention to plant-derived products has greatly increased. The aim of this study was to compare the cytotoxicity of hydro-alcoholic extracts of nettle and clove on cancer and normal cells.
Materials & Methods: Hydro-alcoholic extracts of nettle and clove were prepared in different concentrations (25, 100, 400, and 1200 μg / ml) then added to culture medium of breast cancer cells (MCF-7) and normal cells (Huvec) and incubated for 24 or 72 h. At the end of incubation, cytotoxicity was assessed by MTT assay and apoptosis by acridine orange-ethidium-bromide dual staining. The obtained data were analyzed using SPSS software and Duncan's multiple comparisons.
Results: The addition of hydroalcoholic extracts of both nettle and clove at the highest used concentration (1200 μg/ml) after 24 and 72 hreduced cell proliferation significantly compared to other treatment and control groups (p<0.05). The addition of the highest concentration of both hydro-alcoholic extracts of clove and nettle to normal cells reduced cell proliferation significantly compared to other treatment groups (p<0.05).
Conclusion: The results of this study showed that the hydro-alcoholic extracts of nettle and clove inhibit the proliferation of breast cancer cells (MCF-7).
Full-Text [PDF 1024 kb]   (3016 Downloads)    
Type of Study: Research | Subject: General

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.